戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e countries who tested TST-positive (>/=5 mm induration).
2 the upper outer quadrant with overlying skin induration.
3 iotherapy boost did not increase the risk of induration.
4 lia, followed by chronic neuropathy and skin induration.
5 m away but within the area of the late-phase induration.
6 er was noninferior to WBI in terms of breast induration.
7 e was a risk factor for radiation-associated induration.
8 rimary end point was 3-year grade 2-3 breast induration.
9  PBI was noninferior to WBI regarding breast induration.
10  the 36 women included scarring (36 [100%]), induration (30 [83%]), and hyperpigmentation (29 [81%]).
11 n (10% [8-12%] vs 14% [12-17%], p=0.003) and induration (6% [5-8%] vs 14% [11-16%], p<0.001).
12 , we evaluated the distribution of skin size induration after intradermal injection of PPD among 364
13 immunity based on the extent of erythema and induration after intradermal VZV antigen injection.
14 licited dose-dependent increases in erythema/induration and cellular infiltrates.
15 d MBP1 (10 microM) each produced perceptible induration and erythema with moderate cellular infiltrat
16 of grade 1 injection-site reactions (two for induration and one for erythema or swelling).
17 d papule in his right axilla with increasing induration and pain.
18 t common adverse effects were injection site induration and tenderness.
19  of both a change in the size of the zone of induration and the age of the person being tested.
20 moderate injection site pain and tenderness, induration, and erythema.
21 ding erythema, pruritis, swelling, bruising, induration, and pain.
22 e were more local reactions (pain, erythema, induration, and warmth) and systemic reactions (chills,
23 rimary end point was 3-year grade 2-3 breast induration assuming noninferiority regarding locoregiona
24 upplemented with BCSO, the total diameter of induration at 24 h and individual responses to tetanus t
25 r does not increase the occurrence of breast induration at 3 years compared with a dose of 50 Gy in 2
26 t Test 2 there was a significant increase in induration at 48 h (mean, 7.8 mm; p < 0.001), no differe
27                                              Induration at the MRV-MNP application site was the most
28 e tuberculin skin test positive (ie, >/=5 mm induration) at enrolment received a substantial benefit
29    There were more positive results (> 15 mm induration) at Test 2 compared with Test 1 at 48 h (19 v
30 an subjects exhibited decreased erythema and induration, CD4(+) and CD8(+) T-cell infiltration, and a
31 unlikely to cause the redness, swelling, and induration characteristic of the peak (6 h) late-phase c
32 cancer or DCIS did not result in more breast induration compared with standard fractionated therapy.
33                                          TST induration diameter and IFN-gamma responses were correla
34 hs) and clinical assessment (telangiectasia, induration, edema, and pigmentation).
35    No significant differences in PPD-induced induration, epidermal activation and thickening or numbe
36                                              Induration, erythema, or local pain at the injection sit
37  Adverse reactions (local redness, swelling, induration, fever>39 degrees C) were reported by 5.3% of
38 survival proportion was 84.6% for those with indurations greater than 10 mm, compared with 45.0% for
39                  Two vaccinees had transient induration &gt; 1 cm in diameter at the injection site.
40 ctively compared for 37 tuberculin-positive (induration &gt; or = 5 mm) and 284 tuberculin-negative (ind
41 leishmanin test converted after vaccination (induration &gt; or =5 mm) had a significantly lower frequen
42 ity (DCH) response to the third vaccination (induration &gt;/=5 mm).
43  immunodeficiency virus infection, skin test induration &gt;=10 mm, shared bedroom with an index patient
44                TST conversion was defined as induration &gt;=5 mm after a negative TST result (0 mm) at
45                                    Positive (induration, &gt; or =10 mm) tuberculin skin test results we
46 ubjects with positive tuberculin skin tests (induration, &gt; or =5 mm) with purified protein derivative
47 ere mild-to-moderate implant-site reactions (induration, hematoma, pain).
48 thy, tuberculin skin test-positive (>/=15-mm induration), HIV-negative South African adults.
49 test results were recorded in millimeters of induration in 95 (25%); and 100 (27%) reported collectin
50  = .02) but slightly greater absence of skin induration in follow-up (84.5% vs 81.2%, P = .02).
51                   Subjects with anergy (0 mm induration in reaction to PPD and candida antigens) were
52 ly for the marked effect of BCG-attributable induration in the very young.
53 an 10 mm, compared with 45.0% for those with indurations less than 5 mm.
54 on > or = 5 mm) and 284 tuberculin-negative (induration &lt; or = 2 mm) persons.
55                                   Serial PPD induration, lymphoproliferation, and interferon-gamma re
56 ion-site erythema (n=158) and injection-site induration (n=153).
57 s 20 percent or more among most persons with induration of 10 mm or more on a tuberculin skin test an
58 ildren five years of age or younger who have induration of 10 mm or more on a tuberculin skin test.
59 ho are receiving infliximab therapy and have induration of 15 mm or more on a tuberculin skin test.
60           Leishmanin skin conversion with an induration of 5 mm or more in either group was associate
61 ercent) had a positive tuberculin skin test (induration of at least 10 mm), including 3 of the child'
62            Variant reactivity was defined as induration of less than 10 mm at 72 hours that, when rea
63 evealed an enlarged prostate with an area of induration of the left, normal rectal tone, and guaiac-n
64                 Six patients displayed woody induration of the muscles of the legs, thighs, and forea
65 aracterized by an insidious onset of massive induration of the subcutaneous tissue involving the limb
66 ation take rates, lesion size, erythema, and induration or in serum neutralizing-antibody response we
67 or breast shrinkage, breast edema, tumor bed induration, or pigmentation.
68 with coincident uveitis and cutaneous tattoo induration over an 18-month period.
69 n [33%] vs nine [43%] had either erythema or induration [p=0.97]), nor did laboratory safety measures
70        Following high-dose infection, cB6 FP induration peaked at 4 weeks and was maintained for 12 w
71 e area (r = 0.62-0.75), erythema (r = 0.39), induration (r = 0.24) and scale (r = 0.38).
72  IM groups, and mild to moderate erythema or induration reported commonly in the SC groups.
73  and 11 (34%) low risk individuals developed induration resembling DTH, and the cellular infiltrates
74 ncy virus (HIV) infection is associated with induration size among tuberculin reactors, a cross-secti
75 due to cutaneous anergy, to be PPD reactors, induration size was not associated with HIV infection am
76                                       Median induration size was similar among HIV-seropositive (20.5
77                      Smaller tuberculin test induration sizes suggest eligibility for tuberculosis ch
78                      However, rates of local induration, systemic reactions, adverse events (AEs), an
79        In START-A, moderate or marked breast induration, telangiectasia, and breast oedema were signi
80 ed physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95% CI, 1.
81 ST were 0.80 (95% CI, 0.74-0.87) at the 5-mm induration threshold, 0.81 (95% CI, 0.76-0.87) at the 10
82 ensitivity of the TST at both 5-mm and 10-mm induration thresholds were 0.79 (5-mm: 95% CI, 0.69-0.89
83                        However, lack of skin induration to intradermal injection of PPD or PPD anergy
84 clinician-reported moderate or marked breast induration was 11.5% for the control group, 10.6% for te
85                           The 3-year rate of induration was 9.7% for WBI and 5.1% for PBI (P = .014).
86                                              Induration was not sustained in cLTalpha(-/-) FPs that c
87                          The 3-year rates of induration were 11.8% (95% CI, 9.7% to 14.1%) in the 50-
88                       Transient erythema and induration were more common after intradermal administra
89 njection-site reactions (itch, erythema, and induration), which occurred in 73 (84%) patients, and al
90 iolaceous rim or color, warmth to the touch, induration, white-yellow or waxy appearance, shiny white
91 reast size was significantly associated with induration with a 3-year incidence of 13% (WBI) and 6% (